Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

NCT03238703 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Administrative closure based on sponsor recommendation, prior to subject enrollment

Conditions

HER2/Neu Negative
Invasive Breast Carcinoma
Postmenopausal
Stage 0 Breast Cancer
Stage IA Breast Cancer

Interventions

DRUG: Anastrozole
DRUG: Exemestane
OTHER: Laboratory Biomarker Analysis
DRUG: Letrozole
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Tamoxifen Citrate
DRUG: Toremifene Citrate

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]